Fidah bin Ismail Alsagoff active positions
| Companies | Position | Start | End |
|---|---|---|---|
Tychan Pte Ltd.
 Tychan Pte Ltd. BiotechnologyHealth Technology Tychan Pte Ltd. is a clinical-stage biotechnology company based in Singapore that focuses on developing life-saving treatments for emerging infections through disruptive technologies. Tychan was founded by Professor Ram Sasisekharan of Massachusetts Institute of Technology (MIT)/Singapore MIT Alliance for Research and Technology (SMART) and Professor Ooi Eng Eong of Duke-National University of Singapore (Duke-NUS) Medical School, both of whom have expertise in biologics development and biology of acute viral infections. The private company is based in Singapore, Singapore, and Randall E. Woods has been the CEO of the company since 2021. The Singaporean company works closely with regulatory authorities to accelerate the translation from non-clinical studies to clinical trials for emerging pathogens. Temasek Holdings is the founding investor of Tychan. | Director/Board Member | - | - |
Career history of Fidah bin Ismail Alsagoff
Statistics
International
| Singapore | 2 |
Operational
| Director/Board Member | 1 |
Sectoral
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Tychan Pte Ltd.
Tychan Pte Ltd. BiotechnologyHealth Technology Tychan Pte Ltd. is a clinical-stage biotechnology company based in Singapore that focuses on developing life-saving treatments for emerging infections through disruptive technologies. Tychan was founded by Professor Ram Sasisekharan of Massachusetts Institute of Technology (MIT)/Singapore MIT Alliance for Research and Technology (SMART) and Professor Ooi Eng Eong of Duke-National University of Singapore (Duke-NUS) Medical School, both of whom have expertise in biologics development and biology of acute viral infections. The private company is based in Singapore, Singapore, and Randall E. Woods has been the CEO of the company since 2021. The Singaporean company works closely with regulatory authorities to accelerate the translation from non-clinical studies to clinical trials for emerging pathogens. Temasek Holdings is the founding investor of Tychan. | Health Technology |
